Juan Carlos Kaski

Keld Per Kjeldsen

This European Society of Cardiology (ESC) Handbook on Cardiovascular Pharmacotherapy has been developed by experts from the ESC Working Group on Cardiovascular Pharmacotherapy. Its recommendations are aligned with the ESC Clinical Practice Guidelines and based on the most recent scientific evidence in cardiovascular pharmacology and pharmacotherapy. The Handbook provides up-to-date information on pharmacotherapy for cardiovascular disease prevention, and treatment of cardiovascular disease, including ischaemic heart disease, heart failure, arrhythmias, and structural heart disease. The Handbook also deals with the important problems of cardiovascular pharmacotherapy in pregnancy and lactation, kidney insufficiency, and liver disease as well as focusing on major drug interactions, a topic of extreme importance in clinical practice. Two large sections of the book provide a comprehensive A-Z formulary of cardiac and non-cardiac pharmacological agents with practical and accessible information on the most important pharmacological aspects of these agents and their use in clinical practice. The Handbook represents essential reading for cardiologists, general practitioners, internal medicine specialists, anaesthetists, clinical pharmacologists, geriatricians, obstetricians, and cardiovascular nurse consultants. Junior doctors and trainees in all these specialties are also likely to find this book of help. The print edition comes with full access to the online version that will be updated at yearly intervals to keep it up to date.

The ESC Handbook on Cardiovascular Pharmacotherapy

Angina pectoris with normal coronary arteriograms is a common entity which has puzzled cardiologists almost since the advent of coronary arteriography. Despite major advances in the understanding of the pathophysiology of angina in recent years and a multitude of studies on the subject, the cause and mechanisms underlying the syndrome of angina with normal coronary arteries remain unknown. Indeed, results of investigations are controversial and speculation still prevails regarding the nature of the so called `Syndrome X'. Almost every important aspect of Syndrome X has been tackled in the book and the reader is exposed not only to the cardiologists' opinion, but also to the authoritative views of the gastroenterologists, gynaecologists and psychiatrists, extremely well represented in this monograph. The book deals with `cardiologists' Syndrome X' and not the metabolic entity termed `Syndrome X'. The possible connection between the two, however, is discussed. Angina with Normal Coronary Arteries: Syndrome X contributes to the understanding of Syndrome X and helps clinicians manage their Syndrome X-patients better and investigators to open new avenues for research.

Angina Pectoris with Normal Coronary Arteries: Syndrome X

The ESC Handbook on Cardiovascular Pharmacotherapy, based on the most recent guidelines in cardiovascular pharmacology, and containing a comprehensive A-Z formulary of common and less commonly used cardiac drugs and drug groups, provides practical and accessible guidance on all areas of drugprescribing.Previously published as Drugs in Cardiology, this new edition has been developed by the ESC Working Group on Cardiovascular Pharmacology. Pharmacology is an integral aspect in almost all disciplines within cardiology and all cardiologists use cardiovascular drugs.Completely updated and aligned with the ESC Clinical Practice Guidelines for prescribing, this handbook is essential reading for consultants, registrars in training, general practitioners, specialist cardiac nurses and cardiovascular pharmacologists.

Derek J. Hausenloy

Bernard John Gersh

Derek M. Yellon

Much has been written about reperfusion injury in the past decade but unfortunately the information has been generally presented in the form of original specialist papers and little if any integral publication exists on the topic, summarising and analysing the clinical impact of the condition and its management. The pathophysiology and molecular mechanisms of reperfusion injury are complex and, regarding diagnosis, individual diagnostic techniques have been proposed but without a proper assessment of the relative values of these methods. A publication dealing with integral diagnostic strategies would be welcome by the managing physician. Management of the condition is also problematic, as strategies that appear to work in the experimental models do not translate into beneficial interventions in patients. There is a need for these issues to be addressed and discussed in a monographic fashion. Management of Myocardial Reperfusion Injury will tackle these issues in a modern and systematic way and the information will be delivered in a fashion that will be appealing to the reader.

Management of Myocardial Reperfusion Injury

David W. Holt

The spectrum of unstable coronary syndromes has been the object of steadily increasing research particularly in respect of novel diagnostic and treatment modalities. Although the WHO criteria for the diagnosis of acute myocardial infarction have been known for decades, there is still much debate as to the proper use of these, especially the handling of biochemical markers. Traditional enzymes have limitations in diagnostic power and new markers have unclarified applicability with regard to standardisation of assays and decision limits. Furthermore, the growing understanding of the conception of minimal myocardial damage in the borderzone between unstable angina pectoris and myocardial infarction necessitates refinement in the definitions of the various entities within the kaleidoscope of acute myocardial ischaemia. There has been a strong impetus within the European Society of Cardiology to present this subject to a broad audience of cardiologists, and as a consequence the theme of biochemical markers has become an important constituent of the Education and Training Programmes of the Society. This book has fundamental implications for the overall comprehension of this complex area. This book on myocardial damage, compiled by international experts, will truly appeal to the basic scientist as well as the clinician searching for updated knowledge of the pathophysiology and risk stratification of unstable coronary syndromes.

Early Detection by Novel Biochemical Markers

Myocardial Damage

Pablo Avanzas

This book is intended for general cardiologists and other physicians involved in the care of patients with chronic stable angina (CSA). The goal of this book is to update clinicians on recent data on the medical management of patients with CSA. Ischemic heart disease remains a major public health problem. Chronic stable angina is the initial manifestation of ischemic heart disease in approximately one half of patients. Stable coronary artery disease is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischaemia or hypoxia, which are usually inducible by exercise, emotion or other stress and reproducible—but, which may also be occurring spontaneously. Such episodes of ischaemia/hypoxia are commonly associated with transient chest discomfort (angina pectoris). The aim of the management of CSA is to reduce symptoms and improve prognosis. The management of these patients encompasses lifestyle modification, control of coronary artery disease risk factors, evidence-based pharmacological therapy and patient education. All patients with stable angina should be offered optimal medical treatment, defined as one or two anti-anginal drugs as necessary, plus drugs for secondary prevention of cardiovascular disease. Regarding the role of revascularization, randomised trials provide compelling evidence that myocardial revascularisation by coronary artery bypass grafting or by percutaneous coronary intervention improves symptoms of angina relative to continued medical treatment.

Juan Carlos Kaski

About

Books

Join the club